Skip to main content
SpringerLink
Log in

Methotrexate-induced oral mucositis and salivary methotrexate concentrations

  • Original Articles
  • Methotrexate Mucositis
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

We examined the plasma and saliva levels of methotrexate (MTX) achieved during the treatment and rescue periods of ten patients receiving 42-h MTX infusions followed by citrovorum rescue. Saliva MTX levels were generally 1%–2% of the simultaneous plasma levels. Four patients developed severe oral mucositis; three patients developed mild to moderate oral toxicity, and three others had no evidence of mucositis. MTX levels in the patients with severe mucositis were not higher and did not persist longer than the levels achieved in patients with mild or absent toxicity. Attempts at reducing the severity of oral mucositis with topical citrovorum mouth-washes or with atropine to suppress salivation were unsuccessful. MTX-induced oral mucositis is not related to salivary MTX concentrations, and the use of topical citrovorum therapy or the supression of salivation does not appear to ameliorate this toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bertino, J. R., Fischer, G. A.: Techniques for study of resistance to folic acid antagonists. Methods Med. Res. 10, 297–307 (1964)

    Google Scholar 

  2. Bleyer, W. A.: Forty-two hour methotrexate infusions: An interval report. In: Minutes of the New Drug Liaison Meeting: National Cancer Institute, Bethesda, Md. February 17–18, 1977. Bono, V. H. (ed.) pp. 159–166 on file with the Investigational Drug Branch, N.C.I.

  3. Bleyer, W. A.: Clinical pharmacology of methotrexate. Cancer 41, 36–51 (1978)

    Google Scholar 

  4. Murray, C. et al.: High-dose methotrexate (V-MTX-CF) in osteogenic sarcoma: Detection of MTX in saliva and investigation of changes in taste, weight, and dietary intake. Am. Assoc. Cancer Res. 19, 158 (1978)

    Google Scholar 

  5. Stovner, J., Eugseth, J., Brennhovd, I.: Cancer therapy by intraarterial methotrexate infusion: Protection of mucous membranes by topically applied citrovorum factor with hyaluronidase. Cancer Chemother. Rep. 21, 147–148 (1962)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 3B-12, 200144, Bethesda, Maryland, USA

    A. Oliff & D. G. Poplack

  2. Division of Hematology/Oncology, Childrens Orthopedic Hospital and Medical Center, Department of Pediatrics, University of Washington, Seattle, Washington, USA

    W. A. Bleyer

Authors
  1. A. Oliff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. A. Bleyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. G. Poplack
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oliff, A., Bleyer, W.A. & Poplack, D.G. Methotrexate-induced oral mucositis and salivary methotrexate concentrations. Cancer Chemother. Pharmacol. 2, 225–226 (1979). https://doi.org/10.1007/BF00258300

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00258300

Keywords

Search

Navigation